Myrcludex B is a novel drug candidate for treatment of chronic hepatitis B and chronic hepatitis delta, as well as potentially a range of inflammatory and metabolic diseases. Myrcludex B was originally developed by Professor Stephan Urban (University of Heidelberg, Germany).
Myrcludex B mechanism of antiviral action is the highly specific, highly stable binding and inactivation of the hepatocyte surface protein NTCP. It is the single representative of a novel class of anti-HBV molecules, entry inhibitors. By blocking NTCP, Myrcludex B misdirects HBV and co-infecting HDV to an unproductive pathway and thereby prevents an infection of the cell. This mechanism of action offers the possibility to address the two most important medical needs, namely long-term HBV eradication as well as antiviral activity against hepatitis delta virus (HDV).
Because NTCP is involved in the bile acid transport cycle, the blockade of this target by Myrcludex B can potentially be used for the treatment of various metabolic and inflammatory diseases.
Myrcludex B is a linear 47-amino acid chemically synthesized peptide bearing an N-terminal myristoyl moiety and a C-terminal carboxamide. It is composed of naturally occurring L-amino acids and is derived from the N-terminal domain of the large HBV surface protein. Myrcludex B is manufactured by solid phase chemical synthesis.